Moreover, the NOX1/4 inhibitor setanaxib (GKT137831) was shown to induce remarkable hypoxia-selective cytotoxicity in some HCC cell lines, thus representing a promising drug candidate for cancer therapy [79]. Here, NOX1 is linked to hepatocellular carcinoma.